Mesenchymal Stem Cell (MSC) Osteoprogenitors for Regenerative Medicine (Ref: 13140)Technology #13140
Questions about this technology? Ask a Technology Manager
Mesenchymal stem cell (MSC) osteoprogenitors for regenerative medicine
A new isolated and previously unknown MSC subpopulation that
delivers superior tissue repair capabilities.
Potential for more potent “off-the-shelf” MSC therapeutics.
Imminent launch of a phase I/II clinical trial at Singapore
General Hospital: “Biophysically-Derived Pro-Angiogeneic Mesenchymal Stromal
Cells (MSCs) for the Enhancement of Hematopoietic Recovery after Umbilical Cord
Ongoing pre-clinical evaluation of the use of the
sub-population of MSCs in intervertebral disc repair.
During production of mesenchymal stromal cells (“MSC”) for human use, in vitro culture typically produces a heterogeneous population of cells which have different biological properties such that the therapeutic outcomes can be vastly different.
The Inventors have identified a sub-population of highly osteogenic MSCs in expanded cultures that exhibit superior tissue repair/regenerative potential for applications in hematopoiesis and orthopedics. The enhanced tissue repair/regenerative potential is believed to be due to these cell’s ability to secrete increased amounts of regenerative factors, such as IL-6, IL-8, VEGFA, etc.
A label-free means for isolation of these osteoprogenitor subpopulation has also been devised to facilitate translational efforts.
Deliver consistent MSC subpopulation with enhanced
Increase patient to patient reproducibility
Enhance MSC therapies for regenerative medicines and
Strong IP asset covering the method of producing the MSC
subpopulation and its applications
Technology has been incorporated into a GMP production
process for production of a useful MSC subpopulation to treat cord blood
Phase I/II trials using this MSC subpopulation to boost
blood cell recovery is underway (see above for preclinical data on how
different MSC subpopulations support blood cell recovery).
Main inventor: Dr. Zhiyong Poon.
Intellectual Property Status:
PCT US2015/000029 filed on February 18, 2015 as “Mesenchymal Stem Cell (MSC) Osteoprogenitors for Applications in Bone Marrow Regeneration and Hematopoietic Stem Cell (HSC) Transplants “.
National phases pending in SG, US, EP.
For more information, contact:
NUS Industry Liaison Office
: + 65 6516 7175